Compare · ELUT vs RVMD
ELUT vs RVMD
Side-by-side comparison of Elutia Inc. (ELUT) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELUT and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $39.58B, about 942.4x ELUT ($42.0M).
- RVMD has been more active in the news (15 items in the past 4 weeks vs 2 for ELUT).
- RVMD has more recent analyst coverage (25 ratings vs 0 for ELUT).
- Company
- Elutia Inc.
- Revolution Medicines Inc.
- Price
- $0.99+3.13%
- $186.14+3.91%
- Market cap
- $42.0M
- $39.58B
- 1M return
- +0.59%
- -
- 1Y return
- -53.52%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 2
- 15
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ELUT
- Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
- PRESIDENT AND CEO Mills C Randal converted options into 22,473 shares and covered exercise/tax liability with 8,064 shares, increasing direct ownership by 3% to 441,180 units (SEC Form 4) to cover taxes
- Elutia Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Rakin Kevin
- SEC Form 4 filed by Director Colpman David
- SEC Form 4 filed by Director Makes Brigid
- SEC Form 4 filed by Director Neels Guido J
- CHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 7% to 118,052 units (SEC Form 4) (tax liability)
- CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 4,485 shares, increasing direct ownership by 2% to 480,082 units (SEC Form 4) (tax withholding)
- PRESIDENT AND CEO Mills C Randal covered exercise/tax liability with 9,718 shares and converted options into 27,083 shares, increasing direct ownership by 4% to 426,771 units (SEC Form 4) (tax liability)
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)